



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of

6

Complete if Known

Application Number	10/776,657
Filing Date	February 10, 2004
First Named Inventor	SHARMA, Shubh D.
Art Unit	1626
Examiner Name	
Attorney Docket Number	70025-US04-574

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
GS		US- 6,579,968	06-17-2003	Blood, et al.	
		US- 6,534,503	03-18-2003	Dines, et al.	
		US- 6,515,122	02-04-2003	Lang, et al.	
		US- 6,472,398	10-29-2002	Palucki, et al.	
		US- 6,458,790	10-01-2002	Palucki, et al.	
		US- 6,451,783	09-17-2002	Hadock, et al.	
		US- 6,410,548	01-25-2002	Nargund, et al.	
		US- 6,376,509	04-23-2002	Bakshi, et al.	
		US- 6,350,760	02-26-2002	Bakshi, et al.	
		US- 6,284,735	09-04-2001	Girten et al.	
		US- 6,214,831	04-10-2001	Yokoo, et al.	
		US- 6,207,699	03-27-2001	Rothman	
		US- 6,191,117	02-20-2001	Kozachuk	
		US- 6,162,805	12-19-2000	Hefti	
		US- 6,140,354	10-31-2000	Dax, et al.	
		US- 6,127,424	10-03-2000	Martin, et al.	
		US- 6,033,656	03-07-2000	Mikami, et al.	
		US- 5,965,565	10-12-1999	Chen, et al.	
		US- 5,880,125	03-09-1999	Nargund	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1*
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
GS		WO 00/40247	07-13-2000	Alizyme Therapeutics		
		WO 03/009847	02-06-2003	Amgen, Inc.		
		WO 02/081443	10-17-2003	Chiron Corporation		
		WO 02/059108	08-01-2002	Eli Lilly & Company		
		WO 03/061660	07-31-2003	Eli Lilly & Company		
		WO 01/182210	03-15-2001	Genentech, Inc.		

Package
1 of 4Examiner
Signature

/Golam Shameem/ (09/05/2006)

Date
Considered

09/05/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/776,657
		Filing Date	February 10, 2004
		First Named Inventor	SHARMA, Shubh D.
		Art Unit	1626
		Examiner Name	
Sheet 2 of 6	Attorney Docket Number	70025-US04-574	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
GS ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓		US- 5,877,182	03-02-1999	Nargund, et al.	
		US- 5,804,578	09-08-1998	Chakravarty, et al.	
		US- 5,721,251	02-24-1998	Chen, et al.	
		US- 5,721,250	02-24-1998	Morriello, et al.	
		US- 5,494,919	02-27-1996	Morriello, et al.	
		US- 5,120,713	06-09-1992	Mugica	
		US- 4,937,267	06-26-1990	Holloway, et al.	
		US- 4,680,289	07-14-1987	Applezweig	
		US- 4,626,549	12-02-1986	Molly, et al.	
		US- 4,239,763	12-16-1980	Milavec, et al.	
		US- 4,148,923	04-10-1979	Guidicelli, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁵ -Kind Code ⁶ (if known)				
GS ↓ ↓ ↓ ↓ ↓ ↓		WO 01/21647	03-29-2001	Genset AG		
		WO 02/18437	03-10-2002	Hoffman-LaRoche AG		
		WO 02/079753	10-10-2002	Lion BioScience AG		
		WO 03/013509	02-20-2003	Melacure Therapeutics		
		WO 02/12178	02-14-2002	Melacure Therapeutics		
		WO 01/55107	08-02-2001	Melacure Therapeutics		

Examiner Signature	/Golam Shameem/ (09/05/2006)	Date Considered	09/05/2006
--------------------	------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/776,657
		Filing Date	February 10, 2004
		First Named Inventor	SHARMA, Shubh D.
		Art Unit	1626
		Examiner Name	
Sheet 3	of 6	Attorney Docket Number	70025-US04-574

U. S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
GS		US- 2003/0109556	06-12-2003	Mazur, et al.	
		US- 2003/0083228	05-01-2003	Carpino, et al.	
		US- 2003/0069169	04-10-2003	Macor, et al.	
		US- 2003/0055265	03-20-2003	Binggeli, et al.	
		US- 2003/0055247	03-20-2003	Cosford, et al.	
		US- 2003/0004162	01-02-2003	Treadway	
		US- 2002/0173512	11-21-2002	Moltzen, et al.	
		US- 2002/0143141	10-03-2002	Chen, et al.	
		US- 2002/0137664	09-26-2002	Bakshi, et al.	
		US- 2002/0072604	06-13-2002	Carpino, et al.	
		US- 2002/0004512	01-10-2002	Bakshi, et al.	
		US- 2003/0109556	10-31-2001	Mazur, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
GS 		WO 01/55109 :	08-02-2001	Melacure Therapeutics		
		WO 01/55106 :	08-02-2001	Melacure Therapeutics		
		WO 00/35952:	06-22-2000	Melacure Therapeutics		
		WO 02/068387	09-06-2002	Merck & Co, Inc.		
		WO 02/067869	09-06-2002	Merck & Co., Inc.		
		WO 01/30343 .	05-03-2001	Merck & Co., Inc.		

Examiner Signature	/Golam Shameem/ (09/05/2006)	Date Considered	09/05/2006
--------------------	------------------------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/776,657
Filing Date	February 10, 2004
First Named Inventor	SHARMA, Shubh D.
Art Unit	1626
Examiner Name	
Attorney Docket Number	70025-US04-574

Sheet 4 of 6

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials ^a	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			
GS ↓		WO 98/10653	03-19-1998	Merck & Co., Inc.		
		WO 00/05373	02-03-2000	Millenium Pharmaceutical		
		WO 99/58501	11-18-1999	Novo Nordisk AS		
		WO 03/006620	01-23-2003	Palatin Technologies		
		WO 02/064,091	08-22-2002	Palatin Technologies		
		WO 02/079203	10-10-2002	Pfizer, Inc.		

**Examiner
Signature**

/Golam Shameem/ (09/05/2006)

Data Considered	<p>1. All data from the 1990-1991 season were included in the analysis.</p> <p>2. Data from the 1991-1992 season were included in the analysis for the following variables:</p> <ul style="list-style-type: none"> • Age: Data were available for 1991-1992 for 1991-1992. • Gender: Data were available for 1991-1992 for 1991-1992. • Marital Status: Data were available for 1991-1992 for 1991-1992. • Education: Data were available for 1991-1992 for 1991-1992. • Income: Data were available for 1991-1992 for 1991-1992. • Health Status: Data were available for 1991-1992 for 1991-1992. • Employment Status: Data were available for 1991-1992 for 1991-1992. • Insurance Status: Data were available for 1991-1992 for 1991-1992. • Other Factors: Data were available for 1991-1992 for 1991-1992.
----------------------------	--

09/05/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 144B/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/776,657
--------------------	------------

Filing Date	February 10, 2004
--------------------	--------------------------

First Named Inventor	SHARMA, Shubh D.
----------------------	------------------

Art Unit	1628
----------	------

Examiner Name	
---------------	--

Attorney Docket Number	70025-US04-574
------------------------	----------------

Sheet 5

of

6

Attorney Docket Number

70025-US04-574

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
GS ↓ ↓ ↓		WO 02/47670	06-20-2002	Pfizer, Inc.		
		WO 96/38471	12-05-1996	Pfizer, Inc.		
		WO 02/085925	06-12-2003	Proctor & Gamble Co.		
		WO 01/12176	02-22-2001	Sanofi Synthelabo		
		WO 01/23392	04-05-2001	Trega BioSciences, Inc.		
		WO 01/21634	03-29-2001	Trega BioSciences, Inc.		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
GS		WO 02/47670	06-20-2002	Pfizer, Inc.		
↓		WO 96/38471	12-05-1996	Pfizer, Inc.		
		WO 02/085925	06-12-2003	Proctor & Gamble Co.		
		WO 01/12176	02-22-2001	Sanofi Synthelabo		
		WO 01/23392	04-05-2001	Trega BioSciences, Inc.		
		WO 01/21634	03-29-2001	Trega BioSciences, Inc.		

Package
4 of 4

**Examiner
Signature**

/Golam Shameem/ (09/05/2006)

Date Considered

09/05/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/776,657
Filing Date	February 10, 2004
First Named Inventor	SHARMA, Shubh D.
Art Unit	1626
Examiner Name	
Attorney Docket Number	70025-US04-574

Sheet

6

of

6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GS		"Synthetic Peptides: A Users Guide," GA Grant, editor, W.H. Freeman & Co., New York, 1992 (pp. 11-24)	
		HRUBY, VJ, Al-Obeidi, F., and Kazmierski, W.: BioChem Journal 268:249-262, 1990	
		TONIOLO, C., "Conformationally Restricted Peptides Through Sort-Range Cyclizations," International Journal Peptide Protein Research, 35:287-300, 1990	
		HADLEY, M.E., et al., "Discovery and Deveopment of the Novel Melanogenic Drugs," Integration of Pharmaceutical Discovery and Development: Case Studies, Borschart, et al. editors, Plenum Press, New York (1998)	
		DORR, R.T., et al., "Evaluation of Melanotan-II, A Superpotent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study, Life Sciences 58:1777-1784 (1996)	
		ADAN, R.A.H., "Identification of Antagonists for Melanocrotin MC3, MC4, and MC5 Receptors", European Journal Pharmacology, 269:331-337 (1994)	
↓		MERRIFIELD, R.B., "Solid Phase Synthesis" (Nobel Lecture), Agnew Chem 24:799-810 (1985)	

Examiner
Signature

/Golam Shameem/ (09/05/2006)

Date
Considered

09/05/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.